Bio-Techne (TECH) Stock Price, Fundamentals & Analysis

What TECH does

Bio-Techne (TECH) is a US stock in the Healthcare sector, specifically the Biotechnology industry, headquartered in Minneapolis, United States. The company develops, manufactures, and sells life science reagents, instruments, and services for research, diagnostics, and bioprocessing markets worldwide. It operates through two segments: Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflows, consisting of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. TECH is part of the S&P 500.

Key numbers explained

• The current price is 72.52 USD, reflecting the latest trading value of one share.
• The trailing P/E ratio of 62.5 compares the share price to the last 12 months of earnings per share (1.16 USD), showing how much investors pay for each dollar of recent earnings.
• The forward P/E ratio of 31.4 uses expected future earnings, offering a look at valuation based on what analysts anticipate.
• The dividend yield of 0.44% indicates the annual dividend income relative to the share price, with the exDividendDate set for 24 aug. 2026.
• The beta of 1.28 suggests the stock has historically moved about 28% more than the overall market in either direction.
• The 52-week price range of 43,2 – 72,69 USD shows the lowest and highest traded prices over the past year, with the current price near the high end.
• The price-to-book ratio of 5.37 compares the market price to the company's book value per share, a common way to assess whether a stock trades at a premium to its net assets.

What to watch

Investors tracking TECH often look at its position among peers such as Moderna (MRNA), Humana (HUM), and Bristol Myers Squibb (BMY), as well as other healthcare names like Revvity (RVTY), Labcorp (LH), Henry Schein (HSIC), and Universal Health Services (UHS). General factors that can affect a biotechnology stock include research and development pipeline updates, regulatory decisions, reimbursement trends, and broader market movements. The company's revenue growth, year over year of 1.3% and profitMargin of 15% provide a sense of its current top-line and profitability levels. The debt-to-equity ratio of 13.7% indicates a relatively low level of debt compared to equity. The next earnings report is scheduled for 9 nov. 2026.